Mydekla 60 mg (Daclatasvir) Quantity:28 Tablet/s The extended-release nature of Glynase

The extended-release nature of Glynase XL means tablets should not be split

This information is intended strictly for educational purposes and should not be used as a substitute for professional medical advice

The therapeutic efficacy depends on proper timing and dosing within fertility treatment regimens

Once-Daily Dosing: The pharmacokinetics of Nebivolol allow for convenient once-daily administration

More effective overall blood pressure reduction and stroke/heart attack risk mitigation than single drugs

Mydekla 60 mg (Daclatasvir) Quantity:28 Tablet/s The extended-release nature of Glynase\nProduct Overview \nMydekla 60 mg is a prescription antiviral medication manufactured by Mylan Pharmaceuticals. Each bottle contains 28 filmcoated tablets that deliver a 60 mg dose of daclatasvir, a directacting antiviral agent approved for the treatment of chronic hepatitis C virus (HCV) infection. The product is supplied in a sealed, tamperevident package and is intended for oral administration as part of a comprehensive therapy regimen. Shipping